Kearns Evan
Chief Legal Officer
Kearns Evan has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Dec 30, 2025.
On the most recent filing, Kearns Evan is listed as Chief Legal Officer at Cogent Biosciences, Inc. Inside the rolling window, Kearns Evan reported no open-market purchases and 1 open-market sale totaling $2.5M in COGT.
Companies traded
Other insiders at COGT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.5M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kearns Evan made?
Kearns Evan has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Kearns Evan trade?
Kearns Evan has filed SEC Form 4 disclosures for 1 company, including COGT.
When was Kearns Evan's most recent SEC Form 4 filing?
Kearns Evan's most recent SEC Form 4 filing on Tracefour is dated Dec 30, 2025.
What is Kearns Evan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kearns Evan is listed as Chief Legal Officer.
What is Kearns Evan's total buy and sell value in the current window?
Inside the rolling retention window, Kearns Evan bought $0 and sold $2.5M based on SEC Form 4 filings.
What was Kearns Evan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 65,000 COGT shares on 2025-12-26, worth $2.5M, per SEC Form 4 filings.